Epigenetic Modifications as Biomarkers of Tumor Development, Therapy Response, and Recurrence across the Cancer Care Continuum
Aberrant epigenetic modifications are an early event in carcinogenesis, with the epigenetic landscape continuing to change during tumor progression and metastasis-these observations suggest that specific epigenetic modifications could be used as diagnostic and prognostic biomarkers for many cancer t...
Gespeichert in:
| Veröffentlicht in: | Cancers 2018-04, Vol.10 (4), p.101 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | 101 |
| container_title | Cancers |
| container_volume | 10 |
| creator | Thomas, Margaret L Marcato, Paola |
| description | Aberrant epigenetic modifications are an early event in carcinogenesis, with the epigenetic landscape continuing to change during tumor progression and metastasis-these observations suggest that specific epigenetic modifications could be used as diagnostic and prognostic biomarkers for many cancer types. DNA methylation, post-translational histone modifications, and non-coding RNAs are all dysregulated in cancer and are detectable to various degrees in liquid biopsies such as sputum, urine, stool, and blood. Here, we will focus on the application of liquid biopsies, as opposed to tissue biopsies, because of their potential as non-invasive diagnostic tools and possible use in monitoring therapy response and progression to metastatic disease. This includes a discussion of septin-9 (
) DNA hypermethylation for detecting colorectal cancer, which is by far the most developed epigenetic biomarker assay. Despite their potential as prognostic and diagnostic biomarkers, technical issues such as inconsistent methodology between studies, overall low yield of epigenetic material in samples, and the need for improved histone and non-coding RNA purification methods are limiting the use of epigenetic biomarkers. Once these technical limitations are overcome, epigenetic biomarkers could be used to monitor cancer development, disease progression, therapeutic response, and recurrence across the entire cancer care continuum. |
| doi_str_mv | 10.3390/cancers10040101 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5923356</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2040932653</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-7e975110dd05b7fe40f32a44063743b378ccc6677b8fe0f0bedce0caec8f30613</originalsourceid><addsrcrecordid>eNpdUU1v1TAQtBCIVqVnbsgSFw59dP0R--WCBI-2IBUhocfZcpx1n0tiBzup1Au_HfeDqtSXXWtnxzMeQl4zeC9EC8fORoe5MAAJDNgzss9B85VSrXz-qN8jh6VcQj1CMK30S7LHW8WkXqt98udkChcYcQ6Ofkt98MHZOaRYqC30U0ijzb_qGzR5ul3GlOlnvMIhTSPG-Yhud5jtdE1_YJnqDh5RG_t6c0vOWMVR63Iqhc47pJtbtbXk2qc4h7gs4yvywtuh4OF9PSA_T0-2my-r8-9nXzcfz1dOcjavNLa6YQz6HppOe5TgBbdSghJaik7otXNOKa27tUfw0GHvEJxFt_YCFBMH5MMd77R0480wztkOZsqhGrw2yQbz_ySGnblIV6ZpuRCNqgTv7gly-r1gmc0YisNhsBHTUgwHznRNhTUV-vYJ9DItOVZ7FSWhFVw1oqKO71C3P5TRP4hhYG7iNU_irRtvHnt4wP8LU_wFauekBg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2040932653</pqid></control><display><type>article</type><title>Epigenetic Modifications as Biomarkers of Tumor Development, Therapy Response, and Recurrence across the Cancer Care Continuum</title><source>PubMed Central Free</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Thomas, Margaret L ; Marcato, Paola</creator><creatorcontrib>Thomas, Margaret L ; Marcato, Paola</creatorcontrib><description>Aberrant epigenetic modifications are an early event in carcinogenesis, with the epigenetic landscape continuing to change during tumor progression and metastasis-these observations suggest that specific epigenetic modifications could be used as diagnostic and prognostic biomarkers for many cancer types. DNA methylation, post-translational histone modifications, and non-coding RNAs are all dysregulated in cancer and are detectable to various degrees in liquid biopsies such as sputum, urine, stool, and blood. Here, we will focus on the application of liquid biopsies, as opposed to tissue biopsies, because of their potential as non-invasive diagnostic tools and possible use in monitoring therapy response and progression to metastatic disease. This includes a discussion of septin-9 (
) DNA hypermethylation for detecting colorectal cancer, which is by far the most developed epigenetic biomarker assay. Despite their potential as prognostic and diagnostic biomarkers, technical issues such as inconsistent methodology between studies, overall low yield of epigenetic material in samples, and the need for improved histone and non-coding RNA purification methods are limiting the use of epigenetic biomarkers. Once these technical limitations are overcome, epigenetic biomarkers could be used to monitor cancer development, disease progression, therapeutic response, and recurrence across the entire cancer care continuum.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers10040101</identifier><identifier>PMID: 29614786</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Biomarkers ; Cancer ; Carcinogenesis ; Colorectal carcinoma ; DNA methylation ; Epigenetics ; Metastases ; Non-coding RNA ; Post-translation ; Purification ; Review ; Septin ; Sputum ; Urine</subject><ispartof>Cancers, 2018-04, Vol.10 (4), p.101</ispartof><rights>Copyright MDPI AG 2018</rights><rights>2018 by the authors. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-7e975110dd05b7fe40f32a44063743b378ccc6677b8fe0f0bedce0caec8f30613</citedby><cites>FETCH-LOGICAL-c421t-7e975110dd05b7fe40f32a44063743b378ccc6677b8fe0f0bedce0caec8f30613</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923356/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923356/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29614786$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thomas, Margaret L</creatorcontrib><creatorcontrib>Marcato, Paola</creatorcontrib><title>Epigenetic Modifications as Biomarkers of Tumor Development, Therapy Response, and Recurrence across the Cancer Care Continuum</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Aberrant epigenetic modifications are an early event in carcinogenesis, with the epigenetic landscape continuing to change during tumor progression and metastasis-these observations suggest that specific epigenetic modifications could be used as diagnostic and prognostic biomarkers for many cancer types. DNA methylation, post-translational histone modifications, and non-coding RNAs are all dysregulated in cancer and are detectable to various degrees in liquid biopsies such as sputum, urine, stool, and blood. Here, we will focus on the application of liquid biopsies, as opposed to tissue biopsies, because of their potential as non-invasive diagnostic tools and possible use in monitoring therapy response and progression to metastatic disease. This includes a discussion of septin-9 (
) DNA hypermethylation for detecting colorectal cancer, which is by far the most developed epigenetic biomarker assay. Despite their potential as prognostic and diagnostic biomarkers, technical issues such as inconsistent methodology between studies, overall low yield of epigenetic material in samples, and the need for improved histone and non-coding RNA purification methods are limiting the use of epigenetic biomarkers. Once these technical limitations are overcome, epigenetic biomarkers could be used to monitor cancer development, disease progression, therapeutic response, and recurrence across the entire cancer care continuum.</description><subject>Biomarkers</subject><subject>Cancer</subject><subject>Carcinogenesis</subject><subject>Colorectal carcinoma</subject><subject>DNA methylation</subject><subject>Epigenetics</subject><subject>Metastases</subject><subject>Non-coding RNA</subject><subject>Post-translation</subject><subject>Purification</subject><subject>Review</subject><subject>Septin</subject><subject>Sputum</subject><subject>Urine</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdUU1v1TAQtBCIVqVnbsgSFw59dP0R--WCBI-2IBUhocfZcpx1n0tiBzup1Au_HfeDqtSXXWtnxzMeQl4zeC9EC8fORoe5MAAJDNgzss9B85VSrXz-qN8jh6VcQj1CMK30S7LHW8WkXqt98udkChcYcQ6Ofkt98MHZOaRYqC30U0ijzb_qGzR5ul3GlOlnvMIhTSPG-Yhud5jtdE1_YJnqDh5RG_t6c0vOWMVR63Iqhc47pJtbtbXk2qc4h7gs4yvywtuh4OF9PSA_T0-2my-r8-9nXzcfz1dOcjavNLa6YQz6HppOe5TgBbdSghJaik7otXNOKa27tUfw0GHvEJxFt_YCFBMH5MMd77R0480wztkOZsqhGrw2yQbz_ySGnblIV6ZpuRCNqgTv7gly-r1gmc0YisNhsBHTUgwHznRNhTUV-vYJ9DItOVZ7FSWhFVw1oqKO71C3P5TRP4hhYG7iNU_irRtvHnt4wP8LU_wFauekBg</recordid><startdate>20180401</startdate><enddate>20180401</enddate><creator>Thomas, Margaret L</creator><creator>Marcato, Paola</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180401</creationdate><title>Epigenetic Modifications as Biomarkers of Tumor Development, Therapy Response, and Recurrence across the Cancer Care Continuum</title><author>Thomas, Margaret L ; Marcato, Paola</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-7e975110dd05b7fe40f32a44063743b378ccc6677b8fe0f0bedce0caec8f30613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Biomarkers</topic><topic>Cancer</topic><topic>Carcinogenesis</topic><topic>Colorectal carcinoma</topic><topic>DNA methylation</topic><topic>Epigenetics</topic><topic>Metastases</topic><topic>Non-coding RNA</topic><topic>Post-translation</topic><topic>Purification</topic><topic>Review</topic><topic>Septin</topic><topic>Sputum</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thomas, Margaret L</creatorcontrib><creatorcontrib>Marcato, Paola</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thomas, Margaret L</au><au>Marcato, Paola</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Epigenetic Modifications as Biomarkers of Tumor Development, Therapy Response, and Recurrence across the Cancer Care Continuum</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2018-04-01</date><risdate>2018</risdate><volume>10</volume><issue>4</issue><spage>101</spage><pages>101-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Aberrant epigenetic modifications are an early event in carcinogenesis, with the epigenetic landscape continuing to change during tumor progression and metastasis-these observations suggest that specific epigenetic modifications could be used as diagnostic and prognostic biomarkers for many cancer types. DNA methylation, post-translational histone modifications, and non-coding RNAs are all dysregulated in cancer and are detectable to various degrees in liquid biopsies such as sputum, urine, stool, and blood. Here, we will focus on the application of liquid biopsies, as opposed to tissue biopsies, because of their potential as non-invasive diagnostic tools and possible use in monitoring therapy response and progression to metastatic disease. This includes a discussion of septin-9 (
) DNA hypermethylation for detecting colorectal cancer, which is by far the most developed epigenetic biomarker assay. Despite their potential as prognostic and diagnostic biomarkers, technical issues such as inconsistent methodology between studies, overall low yield of epigenetic material in samples, and the need for improved histone and non-coding RNA purification methods are limiting the use of epigenetic biomarkers. Once these technical limitations are overcome, epigenetic biomarkers could be used to monitor cancer development, disease progression, therapeutic response, and recurrence across the entire cancer care continuum.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>29614786</pmid><doi>10.3390/cancers10040101</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2018-04, Vol.10 (4), p.101 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5923356 |
| source | PubMed Central Free; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals |
| subjects | Biomarkers Cancer Carcinogenesis Colorectal carcinoma DNA methylation Epigenetics Metastases Non-coding RNA Post-translation Purification Review Septin Sputum Urine |
| title | Epigenetic Modifications as Biomarkers of Tumor Development, Therapy Response, and Recurrence across the Cancer Care Continuum |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T02%3A46%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Epigenetic%20Modifications%20as%20Biomarkers%20of%20Tumor%20Development,%20Therapy%20Response,%20and%20Recurrence%20across%20the%20Cancer%20Care%20Continuum&rft.jtitle=Cancers&rft.au=Thomas,%20Margaret%20L&rft.date=2018-04-01&rft.volume=10&rft.issue=4&rft.spage=101&rft.pages=101-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers10040101&rft_dat=%3Cproquest_pubme%3E2040932653%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2040932653&rft_id=info:pmid/29614786&rfr_iscdi=true |